Hoberman Kenneth has filed 5 insider transactions across 2 companies since June 2023.
Most recent transaction: a grant/award of 14718 shares of TG THERAPEUTICS, INC. ($TGTX) on June 12, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 12, 2025 | TG THERAPEUTICS, INC. | $TGTX | Hoberman Kenneth | Director | A | Common Stock | 14718 | $0.00 | 279,653.0000 | 160,336,051 | 5.56% | 0.01% |
| June 12, 2025 | Nuvectis Pharma, Inc. | $NVCT | Hoberman Kenneth | Director | A | Common Stock | 30000 | $0.00 | 133,140.0000 | 19,937,507 | 29.09% | 0.15% |
| June 19, 2024 | TG THERAPEUTICS, INC. | $TGTX | Hoberman Kenneth | Director | A | Common Stock | 22250 | $0.00 | 264,935.0000 | 148,508,465 | 9.17% | 0.01% |
| June 13, 2024 | Nuvectis Pharma, Inc. | $NVCT | Hoberman Kenneth | Director | A | Common Stock | 30000 | $0.00 | 103,140.0000 | 16,559,335 | 41.02% | 0.18% |
| June 16, 2023 | Nuvectis Pharma, Inc. | $NVCT | Hoberman Kenneth | Director | A | Common Stock | 18000 | $0.00 | 73,140.0000 | 14,724,249 | 32.64% | 0.12% |